Toll Free: 1-888-928-9744

Sarcoidosis - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sarcoidosis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Sarcoidosis - Pipeline Review, H1 2016', provides an overview of the Sarcoidosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Sarcoidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcoidosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sarcoidosis
- The report reviews pipeline therapeutics for Sarcoidosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Sarcoidosis therapeutics and enlists all their major and minor projects
- The report assesses Sarcoidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Sarcoidosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Sarcoidosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sarcoidosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Sarcoidosis Overview 6 Therapeutics Development 7 Pipeline Products for Sarcoidosis - Overview 7 Sarcoidosis - Therapeutics under Development by Companies 8 Sarcoidosis - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Sarcoidosis - Products under Development by Companies 11 Sarcoidosis - Companies Involved in Therapeutics Development 12 Araim Pharmaceuticals, Inc. 12 FirstString Research, Inc. 13 PharmaIN Corporation 14 Sarcoidosis - Therapeutics Assessment 15 Assessment by Monotherapy Products 15 Assessment by Target 16 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Drug Profiles 23 ABS-11 - Drug Profile 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 cibinetide - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 eprodisate disodium - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Synthetic Peptide for Sarcoidosis - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Sarcoidosis - Recent Pipeline Updates 32 Sarcoidosis - Dormant Projects 35 Sarcoidosis - Discontinued Products 36 Sarcoidosis - Product Development Milestones 37 Featured News & Press Releases 37 Aug 12, 2015: BELLUS Health narrows timelines for the Phase III study for KIACTA 37 Oct 28, 2014: Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy 38 Sep 19, 2014: Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics' Kiacta™ Using Crowdsourcing And Telemonitoring 39 Oct 10, 2013: Araim Pharmaceuticals' ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
Number of Products under Development for Sarcoidosis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Sarcoidosis - Pipeline by Araim Pharmaceuticals, Inc., H1 2016 12
Sarcoidosis - Pipeline by FirstString Research, Inc., H1 2016 13
Sarcoidosis - Pipeline by PharmaIN Corporation, H1 2016 14
Assessment by Monotherapy Products, H1 2016 15
Number of Products by Stage and Target, H1 2016 17
Number of Products by Stage and Mechanism of Action, H1 2016 18
Number of Products by Stage and Route of Administration, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 22
Sarcoidosis Therapeutics - Recent Pipeline Updates, H1 2016 32
Sarcoidosis - Dormant Projects, H1 2016 35
Sarcoidosis - Discontinued Products, H1 2016 36 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify